Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, CD38 has matured into one of the most contested antibody targets in hematology, with 129 active drug programs, 1,865 patent filings since January 2023, and 322 ongoing Phase 2 and Phase 3 trials. Notably, the field is anchored by three approved products — Janssen’s Daratumumab and Daratumumab/Hyaluronidase, plus Sanofi’s Isatuximab — that together generate over $10B in annual multiple myeloma revenue. Specifically, the competitive frontier has split into three…
Author: Eureka LS
Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, SGLT2 inhibitors have evolved from a Type 2 diabetes class into a multi-indication cardiometabolic platform anchoring 36 approved products, 124 active drug programs, 511 patent filings since January 2023, and 784 ongoing Phase 2 and Phase 3 trials. Notably, the indication expansion across heart failure, chronic kidney disease, and now MASH has converted three flagship molecules — empagliflozin, dapagliflozin, and canagliflozin — into pillars of cardiovascular and renal medicine.…
Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, GDF15 (Growth Differentiation Factor 15) has emerged as one of the most distinctive metabolic targets of the past decade, with 44 active drug programs, 309 patent filings since January 2023, and 7 ongoing Phase 2 trials. Notably, the field has converged on a single mechanistic question: blocking GDF15 to reverse cachexia and restore appetite, while a parallel camp explores GDF15 mimetics for obesity and metabolic disease. Specifically, the competitive…
Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, multiple sclerosis (MS) has one of the most mature disease-modifying therapy (DMT) franchises in modern neurology, with more than 20 approved agents across interferons, fumarates, S1P modulators, anti-CD20 monoclonal antibodies, and now — since 2025 — BTK inhibitors. The Patsnap Eureka pharma-intelligence stack returns 1,030 MS-tagged drug records, 5,351 MS-related patents filed since 2023, and 950 ongoing Phase 2/3 clinical trials. Notably, the 2025 calendar year delivered two first-in-class…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary LAG3 (Lymphocyte Activation Gene-3) has crossed from speculative third-generation checkpoint into commercial reality. Notably, the Patsnap Eureka pharma-intelligence stack returns 121 LAG3-targeting drug records, 2,231 LAG3-related patents filed since 2023, and 134 ongoing Phase 2/3 trials. As a result, bristol Myers Squibb’s Relatlimab (the LAG3 component of the Opdualag fixed-dose combination, approved 2022-03-18 with nivolumab in advanced melanoma; standalone approval 2025-05-30) remains the only commercial LAG3 inhibitor — but the modality…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary STING (Stimulator of Interferon Genes) — a cytosolic innate immunity sensor downstream of cGAS — has had one of the most volatile decades in oncology drug discovery. Notably, after the cyclic-dinucleotide (CDN) STING agonist class largely failed in intratumoral clinical trials (Aduro/Novartis ADU-S100 discontinued; Merck MK-1454 discontinued), the field has rebooted around three new modalities: systemic non-CDN small-molecule agonists (Takeda TAK-676, GSK-3745417, Boehringer Ingelheim BI-1703880), antibody-drug-conjugated and immune-stimulating antibody-conjugates (Mersana, Daiichi…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary CD47 — the “don’t eat me” signal that tumor cells use to evade macrophage phagocytosis — has had the most turbulent clinical decade of any myeloid checkpoint. Notably, the Patsnap Eureka pharma-intelligence stack returns 200 CD47/SIRPα-targeting drug records, 1,474 CD47-related patents filed since 2023, and 52 ongoing Phase 2/3 trials. As a result, the headline event was Gilead’s 2024 discontinuation of magrolimab in MDS/AML after the ENHANCE-3 trial showed insufficient benefit…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Interleukin-2 (IL-2) has gone through three distinct eras of drug development: recombinant-protein era (Proleukin/aldesleukin, approved 1992 — toxic, rarely used), “not-alpha” engineered IL-2 era (Nektar bempegaldesleukin + BMS, failed Phase 3 in 2022, $3.6B writedown), and the current engineered-IL-2 era built on fusion proteins, antibody-fusions, and mRNA delivery. The Patsnap Eureka pharma-intelligence stack returns 163 IL-2-targeting drug records, 2,262 IL-2-related patents filed since 2023, and 16 ongoing Phase 2/3 trials —…
Explore the latest Cystic Fibrosis competitive landscape, key players, pipeline drugs, and market trends. Updated 2026.
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Stem cell therapy has entered a decisive inflection point. The sector’s first-ever FDA approval — Mesoblast’s Ryoncil® (remestemcel-L) in December 2024 — validated the mesenchymal stem cell (MSC) route after two decades of development. Simultaneously, the iPSC-derived cell therapy wave is accelerating: BlueRock Therapeutics initiated a pivotal Phase III for Parkinson’s disease in September 2025, Fate Therapeutics has the broadest off-the-shelf iPSC-NK/T portfolio in clinical trials, and Sana Biotechnology’s hypoimmune iPSC…